[1]
|
Kim, E.H., Larson, J.A. and Andriole, G.L. (2016) Management of Benign Prostatic Hyperplasia. Annual Review of Medicine, 67, 137-151. https://doi.org/10.1146/annurev-med-063014-123902
|
[2]
|
Bostanci, Y., Kazzazi, A., Momtahen, S., Laze, J. and Djavan, B. (2013) Correlation between Benign Prostatic Hyperplasia and Inflammation. Current Opinion in Urology, 23, 5-10. https://doi.org/10.1097/mou.0b013e32835abd4a
|
[3]
|
De Nunzio, C., Kramer, G., Marberger, M., Montironi, R., Nelson, W., Schröder, F., et al. (2011) The Controversial Relationship between Benign Prostatic Hyperplasia and Prostate Cancer: The Role of Inflammation. European Urology, 60, 106-117. https://doi.org/10.1016/j.eururo.2011.03.055
|
[4]
|
Gandaglia, G., Briganti, A., Gontero, P., Mondaini, N., Novara, G., Salonia, A., et al. (2013) The Role of Chronic Prostatic Inflammation in the Pathogenesis and Progression of Benign Prostatic Hyperplasia (BPH). BJU International, 112, 432-441. https://doi.org/10.1111/bju.12118
|
[5]
|
Fibbi, B., Penna, G., Morelli, A., Adorini, L. and Maggi, M. (2010) Chronic Inflammation in the Pathogenesis of Benign Prostatic Hyperplasia. International Journal of Andrology, 33, 475-488. https://doi.org/10.1111/j.1365-2605.2009.00972.x
|
[6]
|
Bastard, J.P., Maachi, M., Lagathu, C., Kim, M.J., Caron, M., Vidal, H., et al. (2006) Recent Advances in the Relationship between Obesity, Inflammation, and Insulin Resistance. European Cytokine Network, 17, 4-12.
|
[7]
|
Akhter, N., Wilson, A., Arefanian, H., Thomas, R., Kochumon, S., Al-Rashed, F., et al. (2023) Endoplasmic Reticulum Stress Promotes the Expression of TNF-α in THP-1 Cells by Mechanisms Involving ROS/CHOP/HIF-1α and MAPK/NF-κB Pathways. International Journal of Molecular Sciences, 24, Article 15186. https://doi.org/10.3390/ijms242015186
|
[8]
|
Khosravi, R., Ka, K., Huang, T., Khalili, S., Nguyen, B.H., Nicolau, B., et al. (2013) Tumor Necrosis Factor-α and Interleukin-6: Potential Interorgan Inflammatory Mediators Contributing to Destructive Periodontal Disease in Obesity or Metabolic Syndrome. Mediators of Inflammation, 2013, Article ID: 728987. https://doi.org/10.1155/2013/728987
|
[9]
|
Sarhang Hasan Azeez, (2023) Influence of IL-10, IL-6 and TNF-α Gene Polymorphism on Obesity. Cellular and Molecular Biology, 69, 277-282. https://doi.org/10.14715/cmb/2023.69.15.46
|
[10]
|
Khanna, D., Welch, B.S. and Rehman, A. (2024) Pathophysiology of Obesity. StatPearls.
|
[11]
|
Leisegang, K., Henkel, R. and Agarwal, A. (2019) Obesity and Metabolic Syndrome Associated with Systemic Inflammation and the Impact on the Male Reproductive System. American Journal of Reproductive Immunology, 82, e13178. https://doi.org/10.1111/aji.13178
|
[12]
|
Bardan, R., Dumache, R., Dema, A., Cumpanas, A. and Bucuras, V. (2014) The Role of Prostatic Inflammation Biomarkers in the Diagnosis of Prostate Diseases. Clinical Biochemistry, 47, 909-915. https://doi.org/10.1016/j.clinbiochem.2014.02.008
|
[13]
|
Bechis, S.K., Otsetov, A.G., Ge, R. and Olumi, A.F. (2014) Personalized Medicine for the Management of Benign Prostatic Hyperplasia. Journal of Urology, 192, 16-23. https://doi.org/10.1016/j.juro.2014.01.114
|
[14]
|
Inamura, S. and Terada, N. (2024) Chronic Inflammation in Benign Prostatic Hyperplasia: Pathophysiology and Treatment Options. International Journal of Urology, 31, 968-974. https://doi.org/10.1111/iju.15518
|
[15]
|
Lee, S.W.H., Chan, E.M.C. and Lai, Y.K. (2017) The Global Burden of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. Scientific Reports, 7, Article No. 7984. https://doi.org/10.1038/s41598-017-06628-8
|
[16]
|
Dobrek, Ł. and Thor, P.J. (2015) Benign Prostatic Hyperplasia—Progress in Pathophysiology and Management. Polski merkuriusz lekarski: Organ Polskiego Towarzystwa Lekarskiego, 39, 263-270.
|
[17]
|
Chu, K.F., Rotker, K. and Ellsworth, P. (2013) The Impact of Obesity on Benign and Malignant Urologic Conditions. Postgraduate Medicine, 125, 53-69. https://doi.org/10.3810/pgm.2013.07.2679
|
[18]
|
Breyer, B.N. and Sarma, A.V. (2014) Hyperglycemia and Insulin Resistance and the Risk of BPH/LUTS: An Update of Recent Literature. Current Urology Reports, 15, Article No. 462. https://doi.org/10.1007/s11934-014-0462-x
|
[19]
|
Traish, A., Bolanos, J., Nair, S., Saad, F. and Morgentaler, A. (2018) Do Androgens Modulate the Pathophysiological Pathways of Inflammation? Appraising the Contemporary Evidence. Journal of Clinical Medicine, 7, Article 549. https://doi.org/10.3390/jcm7120549
|
[20]
|
Blackwell, T.S. and Christman, J.W. (1996) Sepsis and Cytokines: Current Status. British Journal of Anaesthesia, 77, 110-117. https://doi.org/10.1093/bja/77.1.110
|
[21]
|
Molnar-Kimber, K., Yonno, L., Heaslip, R. and Weichman, B. (1993) Modulation of TNFα and Il-1β from Endotoxin-Stimulated Monocytes by Selective PDE Isozyme Inhibitors. Agents and Actions, 39, C77-C79. https://doi.org/10.1007/bf01972726
|
[22]
|
Miłkowska, P., Popko, K., Demkow, U. and Wolańczyk, T. (2017) Pro-Inflammatory Cytokines in Psychiatric Disorders in Children and Adolescents: A Review. In: Pokorski, M., Ed., Pulmonary Care and Clinical Medicine, Springer International Publishing, 73-80. https://doi.org/10.1007/5584_2017_32
|
[23]
|
Cutolo, M., Sulli, A., Capellino, S., Villaggio, B., Montagna, P., Pizzorni, C., et al. (2006) Anti‐TNF and Sex Hormones. Annals of the New York Academy of Sciences, 1069, 391-400. https://doi.org/10.1196/annals.1351.037
|
[24]
|
Fujita, K., Hosomi, M., Nakagawa, M., Tanigawa, G., Imamura, R., Uemura, M., et al. (2013) White Blood Cell Count Is Positively Associated with Benign Prostatic Hyperplasia. International Journal of Urology, 21, 308-312. https://doi.org/10.1111/iju.12243
|
[25]
|
Freedland, S.J. and Aronson, W.J. (2009) Invited Commentary: Lower Urinary Tract Symptoms and Inflammation--Weighing the Evidence. American Journal of Epidemiology, 169, 1291-1293. https://doi.org/10.1093/aje/kwp084
|
[26]
|
Kasturi, S., Russell, S. and McVary, K.T. (2006) Metabolic Syndrome and Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Current Urology Reports, 7, 288-292. https://doi.org/10.1007/s11934-996-0008-y
|
[27]
|
Hung, S., Chung, S. and Kuo, H. (2014) Increased Serum C-Reactive Protein Level Is Associated with Increased Storage Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia. PLOS ONE, 9, e85588. https://doi.org/10.1371/journal.pone.0085588
|
[28]
|
Liao, C., Chung, S. and Kuo, H. (2011) Serum C-Reactive Protein Levels Are Associated with Residual Urgency Symptoms in Patients with Benign Prostatic Hyperplasia after Medical Treatment. Urology, 78, 1373-1378. https://doi.org/10.1016/j.urology.2011.04.076
|
[29]
|
Schenk, J.M., Kristal, A.R., Neuhouser, M.L., Tangen, C.M., White, E., Lin, D.W., et al. (2010) Biomarkers of Systemic Inflammation and Risk of Incident, Symptomatic Benign Prostatic Hyperplasia: Results from the Prostate Cancer Prevention Trial. American Journal of Epidemiology, 171, 571-582. https://doi.org/10.1093/aje/kwp406
|
[30]
|
Kahokehr, A., Vather, R., Nixon, A. and Hill, A.G. (2013) Non‐steroidal Anti‐inflammatory Drugs for Lower Urinary Tract Symptoms in Benign Prostatic Hyperplasia: Systematic Review and Meta‐analysis of Randomized Controlled Trials. BJU International, 111, 304-311. https://doi.org/10.1111/j.1464-410x.2012.11559.x
|
[31]
|
Nygård, L.H., Talala, K., Taari, K., Tammela, T.L.J., Auvinen, A. and Murtola, T.J. (2022) Antidiabetic Drugs, Glycemic Control and Risk of Benign Prostatic Hyperplasia. The Prostate, 83, 246-258. https://doi.org/10.1002/pros.24456
|
[32]
|
Zhang, X., Zeng, X., Dong, L., Zhao, X. and Qu, X. (2015) The Effects of Statins on Benign Prostatic Hyperplasia in Elderly Patients with Metabolic Syndrome. World Journal of Urology, 33, 2071-2077. https://doi.org/10.1007/s00345-015-1550-3
|
[33]
|
El-Shafei, N.H., Zaafan, M.A., Kandil, E.A. and Sayed, R.H. (2023) Simvastatin Ameliorates Testosterone-Induced Prostatic Hyperplasia in Rats via Modulating IGF-1/PI3K/AKT/FOXO Signaling. European Journal of Pharmacology, 950, Article ID: 175762. https://doi.org/10.1016/j.ejphar.2023.175762
|
[34]
|
Cakir, S.S., Ozcan, L., Polat, E.C., Besiroglu, H., Kocaaslan, R., Ötunctemur, A., et al. (2018) Statins Are Effective in the Treatment of Benign Prostatic Hyperplasia with Metabolic Syndrome. The Aging Male, 23, 538-543. https://doi.org/10.1080/13685538.2018.1541979
|
[35]
|
Wang, Z., Yang, S., Li, Y., Zhou, Y., Liu, D., Liu, J., et al. (2023) Simvastatin Improves Benign Prostatic Hyperplasia: Role of Peroxisome-Proliferator-Activated Receptor-γ and Classic Wnt/β-Catenin Pathway. International Journal of Molecular Sciences, 24, Article 4911. https://doi.org/10.3390/ijms24054911
|